Skip to content
Pirarubicin
Pirarubicin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01D: Cytotoxic antibiotics and related substances
— L01DB: Anthracyclines and related substances
— L01DB08: Pirarubicin
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50——1124
Multiple myelomaD009101C90.0———1—1
Enteropathy-associated t-cell lymphomaD058527C86.2———1—1
Wilms tumorD009396———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.0—13——3
Progression-free survivalD000077982—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008—3———3
SarcomaD012509—1———1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.0—1———1
Triple negative breast neoplasmsD064726—1———1
Intravesical administrationD000283—1———1
NephroureterectomyD000074682—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePIRARUBICIN
INNpirarubicin
Description
Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.
Classification
Small molecule
Drug classantineoplastic antibiotics (daunorubicin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1
Identifiers
PDB—
CAS-ID72496-41-4
RxCUI—
ChEMBL IDCHEMBL2354444
ChEBI ID—
PubChem CID3033521
DrugBankDB11616
UNII IDD58G680W0G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,845 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
798 adverse events reported
View more details